Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

NUSEP HOLDINGS LTD04/11/201006/07/2016
NUSEP LTD04/11/2010

Shareholder links

Our website ranking of MEM: rating 3
(3 out of 5)



Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MEM5
Address: 30 Richmond Road Homebush, NSW 2140
Tel:  +61 2 8415 7300

Date first listed: 14/05/2007
Company Secretary: Andrew Metcalfe
Sector: Pharmaceuticals Biotechnology & Life Sciences Industry Group: XHJ
Activities: Memphasys Limited (ASX:MEM) specialises in biological separations for commercial applications. The Company's patented membrane processes enable the selection of high value substances or contaminants from the fluid in which they are contained

News & Events

Expand this box to read and print

The suspension of trading in the securities of Memphasys Limited will be lifted immediately following the release by MEM of an announcement regarding a capital raising.


Placement to raise approximately $1.6M at 2 cents per share. Fully underwritten, non-renounceable entitlement offer to raise up to $1.76M (1 new share for every 9 held on the record date at 2 cents per share). Funds will be used predominantly to continue commercialisation of the Felix System, undertake Felix System clinical trials and other regulatory activities, and to continue the development of other pipeline products with the University of Newcastle research team.


On 10 August 2022, the Supreme Court of Western Australia heard the company's application seeking orders in relation to four inadvertent administrative errors whereby the Company failed to lodge a cleansing notice. The Court has granted orders validating any subsequent offer for sale or sale of the Uncleansed Shares. The company is now able to shift itsfocusto completion of its proposed capital raising, which shall comprise a placement and pro-rata entitlement offer. The comapny will remain in voluntary suspension to facilitate an orderly market in its securities pending release of an announcement with respect to the capital raising, which is anticipated to be on or around Monday, 15 August 2022.


The company releases a cleansing statement in relation to the issue of 1,333,334 Shares, which was completed on 21 October 2019.


The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.


The securities of Memphasys Limited ("˜MEM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of MEM, pending the release of an announcement regarding a court application concerning the failure to lodge cleansing notices in connection with the issue of shares on 3 September 2015, 30 May 2017, 21 October 2019 and 17 July 2020.


we understand that on or about this date the company consolidated its shares 1 for 15


name changed from Nusep Holdings Ltd



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    30/12/2022Alison Coutts392,500$0.014$5,417
    30/12/2022Andrew Goodall1,400,000$0.014$18,900
    30/12/2022Alison Coutts392,500$0.014$5,417
    29/03/2019Andrew Goodall496,843$0.020$9,937
    27/09/2018Marjan Mikel1,000,000$0.012$12,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Robert CookeNon Exec Chairman26/04/2022
    Paul WrightIndependent Director13/03/2020
    Michael AtkinsIndependent Director14/03/2024
    David AliExecutive Director, CEO30/11/2023

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Alison CouttsManaging Director, CEO29/11/201301/12/2023
    Andrew GoodallNon Exec Director14/03/201201/12/2023
    Shane HartwigNon Exec Director31/07/201925/04/2022
    Marjan MikelIndependent Director07/06/201813/03/2020
    John PereiraIndependent Director30/08/201607/06/2018
    Robert GilmourNon Exec Director12/04/201629/09/2016
    Mark GellIndependent Director17/10/201412/04/2016
    Michael GrahamNon Exec Director10/09/201404/01/2016
    Stephen van der MyeNon Exec Director02/12/201328/04/2014
    Prakash PatelDirector, CEO01/12/201210/02/2014
    John ManusuNon Exec Chairman11/09/200629/11/2013
    Hari NairDeputy Chairman, Non Exec Director11/09/200629/11/2013
    Hari NairManaging Director, CEO11/09/200629/11/2013
    Clifford EuNon Exec Director01/12/201229/11/2013
    David RoffeDirector10/10/201130/11/2012
    Iain SorrellDirector11/09/200630/11/2012
    Ward WescottDirector10/10/201130/11/2012
    William SpeeDirector01/07/200919/03/2012
    John O'ConnorDirector10/10/201119/02/2012

    Date of first appointment, title may have changed.